MORRISVILLE, N.C. , Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent) owned by United Therapeutics

MORRISVILLE, N.C. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment Conference , which runs from September 13 – 15, 2021.

No Form 483 observations were issued during 5-day inspection MORRISVILLE, N.C. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morrisville, North

MORRISVILLE, N.C. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 (‘793 patent), owned by United Therapeutics Corporation (UTC) and

Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunity Resubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder Improved balance sheet with private placement and increased financial discipline Company to host webcast and conference call today

MORRISVILLE, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021 . The company will host a webcast and conference call at 8:30 a.m.

MORRISVILLE, N.C. , June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension

MORRISVILLE, N.C. , May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia , will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare

Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous MORRISVILLE, N.C. , May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic

- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery - Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder - Improved financial position with private placement and access to new credit facility - Company to host webcast and conference